EP0300031A4 - Immunosuppressive peptides and methods of use. - Google Patents

Immunosuppressive peptides and methods of use.

Info

Publication number
EP0300031A4
EP0300031A4 EP19880902271 EP88902271A EP0300031A4 EP 0300031 A4 EP0300031 A4 EP 0300031A4 EP 19880902271 EP19880902271 EP 19880902271 EP 88902271 A EP88902271 A EP 88902271A EP 0300031 A4 EP0300031 A4 EP 0300031A4
Authority
EP
European Patent Office
Prior art keywords
methods
immunosuppressive peptides
immunosuppressive
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19880902271
Other languages
German (de)
French (fr)
Other versions
EP0300031A1 (en
Inventor
William S Kloetzer
Robert B Naso
John R Warner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Publication of EP0300031A1 publication Critical patent/EP0300031A1/en
Publication of EP0300031A4 publication Critical patent/EP0300031A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19880902271 1987-01-28 1988-01-25 Immunosuppressive peptides and methods of use. Withdrawn EP0300031A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US750987A 1987-01-28 1987-01-28
US7509 1987-01-28

Publications (2)

Publication Number Publication Date
EP0300031A1 EP0300031A1 (en) 1989-01-25
EP0300031A4 true EP0300031A4 (en) 1990-05-14

Family

ID=21726617

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19880902271 Withdrawn EP0300031A4 (en) 1987-01-28 1988-01-25 Immunosuppressive peptides and methods of use.

Country Status (6)

Country Link
EP (1) EP0300031A4 (en)
JP (1) JPH01501939A (en)
KR (1) KR890700602A (en)
AU (1) AU1366088A (en)
DK (1) DK535988A (en)
WO (1) WO1988005783A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
SE8705197D0 (en) * 1987-12-30 1987-12-30 Jonas Blomberg NEW PEPTIDES, TWO DIAGNOSTIC METHODS USING THE PEPTIDES AND A MEDICATION BASED ON THE PEPTIDES
EP0699758B1 (en) * 1988-12-13 2002-07-24 President And Fellows Of Harvard College Prototype felv isolates for use in disease models and vaccines
US5268455A (en) * 1989-05-25 1993-12-07 Genentech, Inc. Process for making biologically active polypeptides based on transforming growth factor-βsequences
US5061786A (en) * 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
JP2807287B2 (en) * 1989-10-13 1998-10-08 株式会社医学生物学研究所 Peptides and their uses
US5567805A (en) * 1990-03-09 1996-10-22 Administrators Of The Tulane Educational Fund The cellular receptor for the CS3 peptide of human immunodeficiency virus
FR2677654B1 (en) * 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc COMPOUNDS WITH AN IMMUNOGENIC ANTI-CYTOKIN EFFECT, AN ANTIYTOSTATIC IMMUNOGENIC EFFECT OR AN ANTI-HIV INFECTION VACCINE EFFECT.
AU679439B2 (en) * 1992-02-10 1997-07-03 Duke University Use of synthetic peptides to induce tolerance to pathogenic T and B cell epitopes of autoantigens
SE9202318L (en) * 1992-08-10 1994-02-11 Replico Medical Ab New peptides, diagnostic antigens, their use, vaccines and drugs
EP0743949B1 (en) 1994-02-07 1999-12-15 QIAGEN GmbH Process for producing endotoxin-free or endotoxin-poor nucleic acids and/or oligonucleotides for gene therapy
DE4405810A1 (en) 1994-02-23 1995-08-24 Behringwerke Ag Peptides derived from a retrovirus from the HIV group and their use
SE9403526D0 (en) 1994-10-14 1994-10-14 Astra Ab New Peptides
DZ1964A1 (en) * 1995-01-13 2002-10-15 Nika Health Products Ltd New applications of a lysozyme dimer.
SE9501067D0 (en) * 1995-03-24 1995-03-24 Astra Ab New peptides
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
EP0923604A1 (en) * 1996-04-12 1999-06-23 Astra Aktiebolag Cysteine-containing or methioine-containing peptides with immunomodulatory effects
WO1998010792A1 (en) * 1996-09-11 1998-03-19 Prendergast Patrick T Immune direction therapy
SE9603468D0 (en) * 1996-09-23 1996-09-23 Astra Ab New compounds
SE9603462D0 (en) * 1996-09-23 1996-09-23 Astra Ab New compounds
SE9603461D0 (en) * 1996-09-23 1996-09-23 Astra Ab New compounds
IT1307826B1 (en) * 1999-12-16 2001-11-19 Dipartimento Di Medicina Speri DIAGNOSTIC METHOD FOR THE RECOGNITION OF NORMAL ELEUCEMIC MYELOID CELLS, LIGANDS USED IN THAT METHOD AND FORMULATIONS FOR USE
WO2004096841A1 (en) 2003-05-02 2004-11-11 Centre National De La Recherche Scientifique Glut-1 as a receptor for htlv envelopes and its uses
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
DK2376917T3 (en) 2009-01-09 2016-07-18 Centre Nat Rech Scient New receptorbindingsligander, use thereof for the detection of cells of biological interest

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985004871A1 (en) * 1984-04-24 1985-11-07 Scripps Clinic And Research Foundation Leukemia-associated virus immunogen, vaccine and assay
JPS6130600A (en) * 1984-06-20 1986-02-12 オ−ソ・ダイアグノステイツク・システムズ・インコ−ポレ−テツド Htlv test using synthetic peptide
WO1986006414A1 (en) * 1985-04-29 1986-11-06 Genetic Systems Corporation Synthetic antigens for the detection of aids-related disease
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1262014A (en) * 1983-01-07 1989-09-26 Mitsuaki Yoshida Human leukemia virus-related peptides, antibodies of the peptides and a process for production of the antibodies
GB8301928D0 (en) * 1983-01-24 1983-02-23 Nicholson B H Process for producing polypeptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985004871A1 (en) * 1984-04-24 1985-11-07 Scripps Clinic And Research Foundation Leukemia-associated virus immunogen, vaccine and assay
JPS6130600A (en) * 1984-06-20 1986-02-12 オ−ソ・ダイアグノステイツク・システムズ・インコ−ポレ−テツド Htlv test using synthetic peptide
WO1986006414A1 (en) * 1985-04-29 1986-11-06 Genetic Systems Corporation Synthetic antigens for the detection of aids-related disease
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 105, No. 19, November 10, 1986, page 802, Abstract 173060j, Columbus, Ohio, US; & JP-A-61 030 600 (ORTHO DIAGNOSTIC SYSTEMS, INC.), Abstract. *
CHEMICAL ABSTRACTS, Vol. 105, No. 7, August 18, 1986, page 503, Abstract 59310r, Columbus, Ohio, US; R.A. HARRELL et al.: "Suppression of the respiratory burst of human monocytes by a synthetic peptide homologous to envelope proteins of human and animal retroviruses", & J. Immunol. 1986, 136(10), 3517-20, Abstract. *
CHEMICAL ABSTRACTS, Vol. 106, No. 15, April 13, 1987, page 488, Abstract 117946m, Columbus, Ohio, US; M. MITANI et al.: "Suppressive effect on polyclonal B-cell activation of a synthetic peptide homologous to a transmembrane component of oncogenic retroviruses", & Proc. Natl. Acad. Sci. USA, 1987, 84(1), 237-40, Abstract. *
Journal of Experimental Medicine, Vol. 159, March 1984, pages 964-969, CIANCI OLO et al.: "Human malignant and mitogen-transformed cells contain retroviral P15E-related antigen", whole document. *
Journal of Immunology, Vol. 137, No. 9, November 1, 1986, pages 2945-2951; Baltimore, MD, US; T.D. COPELAND et al.: "Envelope proteins of human T cell leukemia virus type I: Characterization by antisera to synthetic peptides and identification of a natural epitope", whole article. esp. the peptide SP-74 on table 1. *
Journal of Virology, Vol. 61, No. 1, January 1987, pages 8-15, Am. Soc. for Microbiology, US; J.H. ELDER et al.: "Localization of neutralizing regions of the envelope gene of feline leukemia virus by using anti-synthetic peptide antibodies", complete document, esp. table 1, page 11. *
Nature, Vol. 311, 11 October 1984, page 515, G.J. CIANCIOLO et al.: "Similarity between p15E of murine and feline leukaemia viruses and p21 of HTLV", whole document. *
Nature, Vol. 312, December 1984, page 496, London, GB; PATARCA et al.: "Similarities among retrovirus proteins", whole document, esp. figure 2. *
Proc. Natl. Acad. Sci. USA, Vol. 83, August 1986, pages 6159-6163, J.J.G. WANG et al.: "Detection of antibodies to human T-lymphotoropic virus type III by using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein", whole document, esp. table 1, page 6161. *
Proc. Natl. Acad. Sci., USA, Vol. 82, February 1985, pages 677-681, N. SAGATA et al.: "Complete nucleotide sequence of the genome of bovine leukemia virus, Its evolutionary relationship to other retroviruses", whole document. esp. figure 3. *
Science, Vol. 230, October 25, 1985, pages 453-455; Am. Ass. for the Adv. of Science, Washington, DC, US; G.J. CIANCIOLO et al.: "Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins", whole document. *
See also references of WO8805783A1 *

Also Published As

Publication number Publication date
EP0300031A1 (en) 1989-01-25
DK535988A (en) 1988-11-25
DK535988D0 (en) 1988-09-27
KR890700602A (en) 1989-04-26
WO1988005783A1 (en) 1988-08-11
AU1366088A (en) 1988-08-24
JPH01501939A (en) 1989-07-06

Similar Documents

Publication Publication Date Title
EP0300031A4 (en) Immunosuppressive peptides and methods of use.
JPS6419053A (en) Novel peptide derivative, manufacture and use
ZA881344B (en) Mycobacterial recombinants and peptides
JPS6460373A (en) Human cells and trioner, antibody and trasformer derived from said cells
GB2210043B (en) Phosphinylcycloalkylcarbonyl and phosphinylcycloalkenylcarbonyl dipeptides
EP0301306A3 (en) Cryostat and assembly thereof
GB2201484B (en) Piston and piston ring
GB2203740B (en) Novel peptides, their preparation and use
HUT47609A (en) Amino and phenoplast substituent
IL87730A0 (en) Peptides and antibodies
ZA884504B (en) Immunosuppressant peptides
IL91335A0 (en) Dna sequence and hepadnavirus
IL86796A0 (en) Peptide derivatives,their preparation and their use
JPS646295A (en) Anf-active peptide
ZA889251B (en) 8,9-annelated-beta-carbolines and 8,9-annelated-3,4-dihydro-beta-carbolines
GB2219327B (en) Cementing method and arrangement
AU3101989A (en) Peptide equivalent of non-peptides and methods of design thereof
KR910007551B1 (en) Polyethylene terephchalate and its use
JPS6425787A (en) Volatile lantanum complex and its use
JPS6431799A (en) Peptide and manufacture
CA58426S (en) Combined mug and megaphone
JPS6425789A (en) Substituted amidephophonate and amidephosphate
SG121593G (en) Alloy and methods of use thereof.
CS976187A1 (en) Oxigen-bridged tetrahydropyridines- parimidines and hexahydropyridines
IE871990L (en) Preparation of pyrazinoisoquinolines and intermediates¹therefor.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19881006

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19900514

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19900629